Nexstim Oyj (NXTMH)
Nasdaq Helsinki · Finland · prices in EUR · close of 27 Oct 2026
Key indicators
| Last close | EUR 8.870 |
|---|---|
| 52-week range | 7.890 – 15.350 |
| Return, 1 month / 3 months | −7.1% / −9.9% |
| Return, 1 year / 3 years | −36.6% / +271.1% |
| Trend | Below its 200-day average |
| RSI (14) | 41 |
| Volatility (1 year) | 44.7% |
| Worst drawdown (1 year) | -46.1% |
| Average daily value traded | 0.05M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Nexstim Oyj is a Finnish medical technology company that develops navigated transcranial magnetic stimulation systems for examining and treating the brain. Its equipment helps clinicians map motor areas of the cortex before neurosurgery and supports rehabilitation and therapy for conditions such as depression and stroke. The company serves hospitals, neurology clinics and research institutions, and it is based in Helsinki, Finland.
Nexstim Oyj trades under the code NXTMH on the Nasdaq Helsinki in Finland, with its price quoted in euros (EUR). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Nexstim Oyj (NXTMH) trades on the Nasdaq Helsinki in Finland. It last closed at EUR 8.870 on 27 October 2026.
Its price-based Market X-Ray is 31 out of 100 (a weak price profile), ranking 151 of 190 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 36.6% and over the last three months it fell 9.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Nasdaq Helsinki
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 32 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -9.7% | ||
| From 52-week high | -41.3% | ||
| Momentum | 33 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -9.9% | ||
| 6-month return | -1.6% | ||
| 12-month return, skipping the last month | -31.8% | ||
| Stability (higher is calmer) | 23 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 44.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -46.1% | ||
| Liquidity | 43 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.05M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +1.4% |
|---|---|
| 1 month | −7.1% |
| 3 months | −9.9% |
| 6 months | −1.6% |
| 1 year | −36.6% |
| 3 years | +271.1% |
| 5 years | +90.8% |
Signals
| 50-day / 200-day average | 9.437 / 9.818 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.394 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Nasdaq Helsinki; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.